Deals
Valeant Offers to Buy Allergan With Pershing’s Support
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. offered to buy Allergan Inc., maker of the Botox wrinkle treatment, in a cash-and-stock deal valued at $45.7 billion in the latest step of the Canadian company’s plan to become one of the world’s largest drugmakers.
Under the deal, which came to light in broad terms yesterday, Allergan investors would receive $48.30 in cash and